---
layout: default
title: Cetrorelix
parent: 僅模型預測 (L5)
nav_order: 231
evidence_level: L5
indication_count: 10
---

# Cetrorelix
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Cetrorelix: From Controlled Ovarian Stimulation to Hypertrichosis

## One-Sentence Summary

Cetrorelix is a GnRH (gonadotropin-releasing hormone) antagonist, internationally approved for controlled ovarian stimulation in assisted reproductive technology (ART), used to prevent premature LH surges during infertility treatment.
The TxGNN model predicts it may be effective for **hypertrichosis**, with **0 clinical trials** and **0 publications** directly supporting this direction.
However, the mechanistic basis for this prediction is weak: hypertrichosis is a non-androgenic hair overgrowth disorder that operates independently of the GnRH–sex hormone axis that Cetrorelix targets.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Controlled ovarian stimulation / infertility (ART) |
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why Is This Prediction Reasonable?

Detailed mechanism of action data for Cetrorelix is not available in the current Evidence Pack. Based on established pharmacology, Cetrorelix is a synthetic decapeptide GnRH antagonist that competitively and reversibly blocks GnRH receptors in the anterior pituitary. This rapidly suppresses LH and FSH secretion without the initial "flare effect" associated with GnRH agonists, leading to reduced gonadal sex steroid output. Its primary clinical role is in ART protocols, where it prevents premature ovulation during controlled ovarian stimulation.

Hypertrichosis refers to excessive hair growth that is **not** androgen-dependent. It is distinct from hirsutism: while hirsutism involves androgen-driven terminal hair growth in androgen-sensitive follicles, hypertrichosis involves lanugo- or vellus-type overgrowth from follicles that are not regulated by sex steroids. Because Cetrorelix acts exclusively through the GnRH → LH/FSH → gonadal steroid axis, its mechanism has no recognized pharmacological target in hypertrichosis pathophysiology.

The high TxGNN prediction score (99.98%) most likely reflects a **knowledge graph phenotype-clustering artifact** rather than true biological signal. Hair-related disease nodes — hypertrichosis, hirsutism, trichomegaly, hair shaft abnormalities — tend to cluster densely in the knowledge graph, causing a drug with known activity in one hair condition (androgen-dependent) to score highly across all hair phenotypes, including unrelated ones. The absence of any supporting clinical or preclinical evidence confirms this interpretation.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The high TxGNN score for hypertrichosis is almost certainly a graph clustering false positive — hypertrichosis is non-androgenic, GnRH antagonism has no mechanistic foothold in this disease, and there is zero supporting clinical or preclinical evidence. Cetrorelix is additionally not registered in Singapore, requiring full regulatory pathway work before any clinical application.

**To proceed, the following is needed:**

- **MOA confirmation:** Retrieve full DrugBank entry for Cetrorelix (DB00050) to formally document GnRH antagonist mechanism and approved indications for the Evidence Pack
- **Singapore regulatory pathway:** Assess HSA registration requirements if any downstream indication is pursued
- **Re-prioritization of predictions:** Among the 10 predicted indications in this pack, **central precocious puberty (rank 10)** is the most mechanistically aligned — GnRH antagonism is directly relevant, and GnRH agonists (leuprolide) are already standard of care for this condition; a GnRH antagonist offers the theoretical advantage of no initial flare. This indication warrants a dedicated literature search as the next step
- **Safety data:** Obtain the Singapore-approved package insert or international label to complete the safety profile (key warnings, contraindications) before any clinical evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

